Search
Gemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemi...
SO-101
go.drugbank.com/drugs/DB05345ExperimentalDoxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Elesclomol
go.drugbank.com/drugs/DB05719InvestigationalElesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad r...
Coagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalCoagulation Factor X is a vitamin K-dependent, liver-produced serine protease that serves as the first enzyme in the coagulation cascade to form fibrin. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigationalZiconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds. … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigationalfailed rather than as an alternative first choice. … is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after another ROS1 inhibitor has
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Delocamten
go.drugbank.com/drugs/DB21711InvestigationalDelocamten has a monoisotopic molecular weight of 377.16 Da. … Delocamten is under investigation in clinical trial NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection
5alpha-androstane-3beta,17alpha-diol
go.drugbank.com/drugs/DB03926ExperimentalIt has been implicated as a regulator of gonadotropin secretion.
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalIt is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Products: VOTRIENT FILM-COATED TABLET 200MG, VOTRIENT FILM-COATED TABLET 400MG